Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
July 18, 2024 5:00 PM EDTPALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (NASDAQ: GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development, said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. His extensive experience in... More
